SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy
November 08 2019 - 8:00AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the
“Company”), a clinical-stage biopharmaceutical company focused on
the development of novel cancer immunotherapies for a broad range
of cancer indications, today announced that it will host a KOL
Symposium for investors on Friday, November 15, 2019 from 8:15 a.m.
to 10:00 a.m. ET in New York, NY.
The KOL Symposium will include an overview of the Company’s
ongoing clinical development programs for galinpepimut-S (GPS),
with a focus on its Phase 3 trial of GPS in acute myeloid leukemia
(AML), which is expected to initiate in the fourth quarter of
2019.
The KOL Symposium will feature presentations and discussions
from internationally renowned experts on immuno-oncology and
myeloid malignancies including:
- Hagop M. Kantarjian, M.D., Chair of the
Department of Leukemia and Associate Vice President for Global
Academic Programs at the University of Texas MD Anderson Cancer
Center and principal investigator of SELLAS’ Phase 3 clinical trial
of GPS in acute myeloid leukemia
- Javier Pinilla-Ibarz, M.D., Ph.D., Senior
Member of the Malignant Hematology & Immunology Program and
Director for Immunotherapy for Malignant Hematology at the H. Lee
Moffitt Cancer Center
- David A. Scheinberg, M.D., Ph.D., Vincent
Astor Chair and Chairman of the Molecular Pharmacology Program and
Founder and Chair of the Center for Experimental Therapeutics at
Memorial Sloan Kettering Cancer Center
- Jeffrey S. Weber, M.D., Ph.D., Deputy Director
of the Perlmutter Cancer Center and Co-Director of the Melanoma
Research Program at the NYU Langone Cancer Center
A live audio webcast of the event will be available under
“Events and Presentations” in the Investors section of SELLAS’
website at www.sellaslifesciences.com/investors. A replay of the
webcast will be available for up to 30 days on SELLAS’ website
following the event.
About SELLAS Life Sciences Group, Inc.
SELLAS is a clinical-stage biopharmaceutical company focused on
novel cancer immunotherapeutics for a broad range of cancer
indications. SELLAS’ lead product candidate, galinpepimut-S (GPS),
is licensed from Memorial Sloan Kettering Cancer Center and targets
the Wilms Tumor 1 (WT1) protein, which is present in an array of
tumor types. GPS has potential as a monotherapy or in combination
to address a broad spectrum of hematologic malignancies and solid
tumor indications. SELLAS has received Orphan Drug designations for
GPS from the U.S. Food and Drug Administration (FDA) and the
European Medicines Agency (EMA) for AML, malignant pleural
mesothelioma (MPM), and multiple myeloma (MM); GPS has also
received Fast Track designation for AML, MPM and MM from the FDA.
SELLAS’ second product candidate, nelipepimut-S (NPS), is a
HER2-directed cancer immunotherapy being investigated for the
prevention of the recurrence of breast cancer after standard of
care treatment in the adjuvant setting. NPS has received Fast Track
status designation by FDA for the treatment of patients with early
stage breast cancer with low to intermediate HER2 expression,
otherwise known as HER2 1+ or 2+, which includes triple negative
breast cancer patients, following standard of care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor ContactsWill O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
Investor RelationsSELLAS Life Sciences Group,
Inc.917-438-4353info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024